Enteric Nervous System Progenitor Cells – For Hirschsprung Disease Treatment
Enteric Nervous System Progenitor Cells – For Hirschsprung Disease Treatment is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Worry-free returns
Worry-free returns
You may return most new, unopened items within 7 days of delivery for a full refund. We'll also pay the return shipping costs if the return is a result of our error (you received an incorrect or defective item, etc.).
You should expect to receive your refund within four weeks of giving your package to the return shipper, however, in many cases you will receive a refund more quickly. This time period includes the transit time for us to receive your return from the shipper (5 to 10 business days), the time it takes us to process your return once we receive it (3 to 5 business days), and the time it takes your bank to process our refund request (5 to 10 business days).
If you need to return an item, simply login to your account, view the order using the "Complete Orders" link under the My Account menu and click the Return Item(s) button. We'll notify you via e-mail of your refund once we've received and processed the returned item.
Delivery and Shipping
Delivery and Shipping
Free standard shipping on all orders under 1 KG
Enteric Nervous System Progenitor Cells – For Hirschsprung Disease ...
Product Details
This product consists of Enteric Nervous System Progenitor Cells – For Hirschsprung Disease Treatment (Clinical Investigation), a preparation of human pluripotent stem cell (hPSC)-derived cells. These cells are intended for ex vivo research applications in tissue regeneration, specifically for colonic tissue affected by Hirschsprung disease (HSCR).
This is a novel investigational cell product developed for research and has no direct commercial or aftermarket interchanges.
- Cell Type: SOX10-positive (60-80%) progenitor cells expressing p75 (97.9%) and CD49d (82.3%).
- Application: Designed for ex vivo transplantation into aganglionic colonic tissue segments.
- Mechanism of Action: Functionally improves tissue contractility through cholinergic and nitrergic pathways.
Part Number Matrix
Use this matrix to confirm equivalent references across OEM and aftermarket.
| Brand | Part Number | Notes |
|---|---|---|
| Jevans B, et al. | doi:10.1136/gutjnl-2023-331532 | Primary research article; detailed methodology, results, cell characteristics |
| Frith TJR, et al. | Stem Cell Reports 2020;15:557–65 | Referenced protocol development |
| Gogolou A, et al. | Curr Protoc 2021;1:e137 | Referenced protocol details |
Engine & Model Compatibility
Confirm your engine model/year in the table below.
| Disease | Age Range | Gender | Tissue Source | Notes |
|---|---|---|---|---|
| Hirschsprung disease (HSCR) | 2 months–4.5 years | 6 males, 1 female | Colonic tissue from HSCR patients | Surgical discard tissue from 7 patients |
Technical Specs
- Product Type
- Human pluripotent stem cell (hPSC)-derived enteric nervous system (ENS) progenitor cells
- Clinical Application
- Hirschsprung disease (HSCR) tissue regeneration
- Cell Source
- Human embryonic stem cells (H9/WA09, H9-RFP) and induced pluripotent stem cells (SFCi55-ZsGr, MasterShef11, SOX10:GFP)
- Generation Protocol
- 6-day accelerated differentiation via WNT stimulation, TGFβ inhibition, moderate BMP activity, followed by retinoic acid treatment
- Cell Markers
- SOX10 (60-80%), p75 (NGFR) (97.9%), CD49d (82.3%)
- Cell Yield
- 500,000 cells/cm² used in transplantation studies
- Differentiation Potential
- Neurons (TUBB3+, TH+, PGP9.5+, HUC/D+, nNOS+, RET+, CALB2+, TRKC+) and glia (SOX10+, S100β+)
- Cryopreservation
- Cells maintain viability and differentiation potential after cryopreservation
- Integration Capability
- Cells integrate, migrate, and differentiate within HSCR tissue ex vivo
- Functional Effect
- Significant increase in basal contractility and electrical field stimulation (EFS) response in HSCR tissue
- Observed Migration
- Progressive migration from transplant site observed over 21 days
- Operating Temperature
- 37°C, 5% CO₂ (standard cell culture conditions)
- Delivery Method
- Injection via blunt Hamilton syringe with glass capillary needle (60 μm tip)
- Injection Volume
- 4 μL (500,000 cells total)
- Injection Rate
- 0.5 μL/min
- Culture Duration
- 21 days, with media changes every other day
- Product Dimensions
- 26.5" L x 15.0" W x 0.5" H
What’s in the Box
- Cryopreserved Human ENS Progenitor Cells
- Resuspended in DMEM F12 culture medium with N2, B27, and Primocin supplements
- Total Cell Count: ~500,000 cells per application
Installation Notes
- Thaw frozen donor cells according to the protocol and resuspend at a concentration of approximately 125,000 cells/μL.
- Prepare a blunt Hamilton syringe fitted with a glass capillary needle (60 μm tip).
- Carefully inject a total volume of 4 μL (containing 500,000 cells) into the target tissue area.
- Administer the injection at a slow, controlled rate of 0.5 μL per minute to ensure proper distribution.
- After the full volume is delivered, hold the needle in place for 1 minute before withdrawal to minimize cell leakage.
- Culture the transplanted tissue for 21 days under standard conditions (37°C, 5% CO₂), ensuring media is changed every other day.
Troubleshooting & FAQ
How is cell viability and identity confirmed?
Cells are confirmed for viability and differentiation potential post-cryopreservation. Key markers for identity include SOX10 (60-80%), p75 (NGFR) (97.9%), and CD49d (82.3%), ensuring the correct progenitor cell type is used.
What is the expected functional outcome?
In ex vivo studies, transplantation resulted in a significant increase in basal contractility and electrical field stimulation (EFS) response in treated HSCR tissue. A 68.4% positive increase in EFS response was observed across 19 paired tissue segments.
What are the limitations of the current data?
This product is based on an ex vivo model with a small patient sample (n=7) and a short 21-day timeframe. The model lacks immune system interactions, and long-term safety and efficacy data are needed. The removal of the mucosal layer for sterility is another limitation.
Is there an optimal cell dosage?
Optimal cell dosing information is still under investigation. The current protocol is based on a dosage of 500,000 cells per transplant, which has demonstrated functional improvement in the ex vivo model.
How were the functional improvements validated?
The improvements were validated via organ bath contractility assessments. The effects were confirmed to be neuronally-mediated, as they were blocked by the neurotoxin Tetrodotoxin (TTX).
OEM vs. Aftermarket?
This listing is an aftermarket replacement (not OEM). Built to OEM-level specifications with comparable materials. Manufactured in an ISO 9002 facility, batch-inspected for consistency.
Shipping speed & cost
We ship worldwide quickly—typical transit 5–15 days. Standard shipping is free; expedited options appear at checkout where available.
Warranty & returns
Covered by a 1-year warranty against manufacturing defects under normal use. If issues arise, contact support with your order details. Returns are accepted within our standard window (unused & in original condition). See our policy page or reach out for instructions.
Safety & Important Info
- Verify all specifications and source documentation against your research protocol. If anything differs—even if your model appears compatible—do not purchase.
- This is an aftermarket replacement, not an OEM component.
- Professional installation is recommended for safety and performance.
About Sea Sierra
- Pro-Grade Standards — We supply marine parts engineered to OEM-level tolerances and tested for real-world conditions.
- Fast Global Fulfillment — Free standard delivery to most regions in 5–15 days.
- Manufacturer-Direct Value — Fair pricing without compromising on materials or QC.
Payment & Security
Payment methods
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
